Navigation Links
Cancer vaccine impact limited unless drug industry focuses on difficult-to-treat tumors
Date:11/21/2011

Drug companies currently developing therapeutic cancer vaccines may be determining the cancers they target based on the number of annual cases, not the number of deaths they cause.

This approach may limit the patient benefits of such drugs, according to a new University of Michigan report.

Therapeutic vaccines, an alternative form of cancer treatment that may be more effective than traditional cancer therapies, are currently being tested in clinical trials around the world.

Early studies on these vaccines, which trigger patients' immune systems to attack cancer cells, have shown they may offer new hope for those suffering from difficult-to-treat cancers.

"In 2011, there were about 230 clinical trials for therapeutic vaccines targeting 13 different types of cancer," says Matthew Davis, M.D., M.A.P.P., associate professor of pediatrics, internal medicine, and public policy at the University of Michigan Health System and Gerald R. Ford School of Public Policy.

"If a cancer is more commonly diagnosed in the United States, it is significantly more likely to have therapeutic vaccines in clinical trials," Davis adds. "Focusing on annual incidence is a very common approach by drug companies in developing new therapies."

Therapeutic vaccine development should focus on cancers with higher mortality rates, creating more potential to improve patient outcomes, Davis suggests.

"The lack of a connection between therapeutic cancer vaccine development and cancer deaths means that vaccine development in this arena today may not best serve the needs of cancer patients tomorrow," Davis says. "As a primary care doctor, I would like to see innovations with therapeutic vaccines that target cancers where our current therapies are less effective than average."

Davis and co-author Elias Dayoub, a second-year medical student, emphasize that lung cancer and pancreatic cancer are two tumor types where the five-year survival is lower than average and the number of patients newly diagnosed each year is higher than average.

"Fortunately for patients, there are already some late-stage clinical trials in progress for patients with cancers of the lung and pancreas," Davis says. "Based on the typical time course for trials and licensure, if these vaccines are safe and effective, we may able to use them to help patients as early as 2020 and perhaps earlier."

The cancers with the highest number of active clinical trials worldwide in 2011 are melanoma (40), breast (34), lung (30), prostate (22), and brain (20).

The five cancers with the highest five-year mortality (estimated by the authors, based on current U.S. data) are lung (186,000), pancreas (40,000), colon (35,000), breast (21,000) and liver and bile duct (21,000), for a total of 303,000 deaths. There are currently 90 therapeutic vaccines in development against these 5 types of cancer.

In contrast, the five cancers with the most active development (146 vaccines in aggregate) target cancers with a lower five-year mortality of approximately 226,000. "This mismatch is unfortunate for patients," says Davis. "Cancers with higher mortality currently have fewer vaccines in development. For therapeutic vaccines to make the biggest difference in cancer care, development must focus more on high-mortality tumors."


'/>"/>

Contact: Lauren McLeod
lemcleod@med.umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Siblings Deeply Affected By Childs Cancer Death
2. Cancer drug cisplatin found to bind like glue in cellular RNA
3. New breast cancer screening guidelines released
4. BRAF addiction of thyroid cancers makes them therapeutically vulnerable
5. IBD patients face increased skin cancer risk
6. FDA Revokes Approval of Avastin for Breast Cancer
7. Colon cancer screening campaign erases racial, gender gaps in use of colonoscopy
8. Tender Breasts From Combo HRT Linked to Higher Cancer Risk
9. Combo hormone therapy has increased breast cancer risk over estrogen alone
10. PBX1 identified as a new pioneer factor underlying progression in breast cancer
11. Cancer Doctors Still Not Great With Patients Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... San Ramon, CA (PRWEB) , ... February 23, 2017 , ... ... Kaplan, MD, FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and ... served as the chairman and CEO of the Virginia Mason Health System in Seattle ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leverages advanced data analytics to accurately understand each Medicare Advantage member’s risk, ... a given population. This new solution helps transform the HCC Risk Adjustment ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  As National Nutrition ... addition, the Company is helping people live healthier ... customized prescription savings programs in all 50 states ... Assistance Program  and  California Prescription Assistance Program . ... Columbia University for nutritious eating habits: ...
(Date:2/23/2017)... MARIETTA, Ga., Feb. 23, 2017  MiMedx Group, Inc. ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of ... quarter and full year ended December 31, 2016. ... Revenue is a 31% increase over full year ...
(Date:2/23/2017)... Korea , Feb. 23, 2017 LG Innotek today ... LED for sterilization applications. As its sterilization performance is 1.5 times ... the short wavelength ultraviolet rays in the range of 200 -- 280nm, ... proliferation of bacteria by destroying their DNA. LG Innotek,s product emits ... ...
Breaking Medicine Technology: